
## **Gregory A Jicha**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6214305/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Examining the association between bloodâ€based biomarkers and human <i>post mortem</i> neuropathology in the University of Kentucky Alzheimer's Disease Research Center autopsy cohort. Alzheimer's and Dementia, 2023, 19, 67-78.	0.8	18
2	Comparison of behaviors characteristic of autism spectrum disorder behaviors and behavioral and psychiatric symptoms of dementia. Aging and Mental Health, 2022, 26, 586-594.	2.8	3
3	Sensory Processing Abnormalities in Community-Dwelling Older Adults with Cognitive Impairment: A Mixed Methods Study. Gerontology and Geriatric Medicine, 2022, 8, 233372142110682.	1.5	6
4	Incident epilepsy in the cognitively normal geriatric population, irrespective of seizure control, impairs quality of life. Epilepsy and Behavior, 2022, 126, 108457.	1.7	4
5	Apolipoprotein E Proteinopathy Is a Major Dementia-Associated Pathologic Biomarker in Individuals with or without the APOE Epsilon 4 Allele. American Journal of Pathology, 2022, 192, 564-578.	3.8	6
6	Amyloid-PET Levels in the Precuneus and Posterior Cingulate Cortices Are Associated with Executive Function Scores in Preclinical Alzheimer's Disease Prior to Overt Global Amyloid Positivity. Journal of Alzheimer's Disease, 2022, 88, 1127-1135.	2.6	5
7	Rural Caregivers: Identification of Informational Needs Through Telemedicine Questions. Journal of Rural Health, 2021, 37, 406-411.	2.9	6
8	Insights From African American Older Adults on Brain Health Research Engagement: "Need to See the Need― Journal of Applied Gerontology, 2021, 40, 201-208.	2.0	10
9	Memory-Related Frontal Brainwaves Predict Transition to Mild Cognitive Impairment in Healthy Older Individuals Five Years Before Diagnosis. Journal of Alzheimer's Disease, 2021, 79, 531-541.	2.6	9
10	Brain arteriolosclerosis. Acta Neuropathologica, 2021, 141, 1-24.	7.7	85
11	MarkVCID cerebral small vessel consortium: I. Enrollment, clinical, fluid protocols. Alzheimer's and Dementia, 2021, 17, 704-715.	0.8	42
12	Gauging Working Memory Capacity From Differential Resting Brain Oscillations in Older Individuals With A Wearable Device. Frontiers in Aging Neuroscience, 2021, 13, 625006.	3.4	8
13	Associations of Future Cognitive Decline with Sexual Satisfaction among Married Older Adults. Clinical Gerontologist, 2021, 44, 345-353.	2.2	3
14	Reduced rank multinomial logistic regression in Markov chains with application to cognitive data. Statistics in Medicine, 2021, 40, 2650-2664.	1.6	1
15	Development of a protocol to assess within-subject, regional white matter hyperintensity changes in aging and dementia. Journal of Neuroscience Methods, 2021, 360, 109270.	2.5	5
16	Diagnostic and prognostic performance and longitudinal changes in plasma neurofilament light chain concentrations in adults with Down syndrome: a cohort study. Lancet Neurology, The, 2021, 20, 605-614.	10.2	29
17	Differences in Symptomatic Presentation and Cognitive Performance Among Participants With LATE-NC Compared to FTLD-TDP. Journal of Neuropathology and Experimental Neurology, 2021, 80, 1024-1032.	1.7	13
18	COVID-19 and the neurological disease therapeutic pipeline. Nature Reviews Neurology, 2021, 17, 71-72.	10.1	2

#	Article	IF	CITATIONS
19	Real-world Site Experiences With GeneMatch. Alzheimer Disease and Associated Disorders, 2021, 35, 148-152.	1.3	0
20	Multi-vendor and multisite evaluation of cerebrovascular reactivity mapping using hypercapnia challenge. NeuroImage, 2021, 245, 118754.	4.2	7
21	Association of Subjective Hearing Loss and Apolipoprotein E ε4 Allele on Alzheimer's Disease Neurodegeneration. Otology and Neurotology, 2021, 42, e15-e21.	1.3	2
22	Brainwaves correlate with senior moments in preclinical older adults: Towards a cognitive screening protocol using a wireless device. Alzheimer's and Dementia, 2021, 17, .	0.8	0
23	Metabolic and cerebrovascular effects of gemfibrozil treatment: A randomized, placeboâ€controlled, doubleâ€blind, phase II clinical trial for dementia prevention. Alzheimer's and Dementia, 2021, 17, .	0.8	0
24	INCREASEâ€DEPTH: MTM and DEPrescribing THerapy recommendations for medicationâ€related problems among elderly adults in the INCREASE trial. Alzheimer's and Dementia, 2021, 17, .	0.8	0
25	Does targeted medication therapy management increase cognitive reserve? Results from the INtervention for Cognitive Reserve Enhancement in delaying the onset of Alzheimer's Symptomatic Expression (INCREASE) study. Alzheimer's and Dementia, 2021, 17, .	0.8	0
26	Preclinical amyloidâ€₽ET SUVr in the precuneus and posterior cingulate associations with MoCA scores are driven by language domain subscores. Alzheimer's and Dementia, 2021, 17, .	0.8	0
27	Cognitive impairment associated with global sensory processing abnormalities. Alzheimer's and Dementia, 2021, 17, e053263.	0.8	0
28	"From Victimhood to Warriors― Super-researchers' Insights Into Alzheimer's Disease Clinical Trial Participation Motivations. Gerontologist, The, 2020, 60, 693-703.	3.9	10
29	Alzheimer Disease Pathology-Associated Polymorphism in a Complex Variable Number of Tandem Repeat Region Within the MUC6 Gene, Near the AP2A2 Gene. Journal of Neuropathology and Experimental Neurology, 2020, 79, 3-21.	1.7	19
30	Behaviors Characteristic of Autism Spectrum Disorder in a Geriatric Cohort With Mild Cognitive Impairment or Early Dementia. Alzheimer Disease and Associated Disorders, 2020, 34, 66-71.	1.3	11
31	Subjective Memory Complaints Are an Important Surrogate for Objective Cognitive Performance in African Americans. Alzheimer Disease and Associated Disorders, 2020, 34, 79-84.	1.3	4
32	Diagnostic and Prognostic Laboratory Testing for Alzheimer Disease. Clinics in Laboratory Medicine, 2020, 40, 289-303.	1.4	2
33	Cardiorespiratory fitness diminishes the effects of age on white matter hyperintensity volume. PLoS ONE, 2020, 15, e0236986.	2.5	11
34	Identifying Adaptive and Maladaptive Behaviors Following a Diagnosis of Mild Cognitive Impairment. Alzheimer Disease and Associated Disorders, 2020, 34, 262-266.	1.3	1
35	Will "social distancing―lead to future "research distancing― A reflection on COVIDâ€19 impacts on Alzheimer's disease research. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12045.	3.7	4
36	COVID-19 and geriatric clinical trials research. Aging Clinical and Experimental Research, 2020, 32, 2169-2172.	2.9	6

#	Article	IF	CITATIONS
37	Limbic-predominant age-related TDP-43 encephalopathy differs from frontotemporal lobar degeneration. Brain, 2020, 143, 2844-2857.	7.6	44
38	Medicationâ€related problems in older adults with and without preclinical Alzheimer's disease: A baseline description from the INCREASE study. Alzheimer's and Dementia, 2020, 16, e044669.	0.8	0
39	Cognitive reserve among potentially inappropriate medication users with and without preclinical Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e044842.	0.8	0
40	Potentially inappropriate medication use associated with lower mobility reserve among individuals with preclinical Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e044879.	0.8	0
41	Cognitive reserve for memory performance is mediated by preclinical frontotemporal and limbic amyloid deposition in subjects with normal cognition in early MCI. Alzheimer's and Dementia, 2020, 16, e046569.	0.8	0
42	Diffuse optical assessment of cerebralâ€autoregulation in older adults stratified by cerebrovascular risk. Journal of Biophotonics, 2020, 13, e202000073.	2.3	10
43	Maximizing Safety in the Conduct of Alzheimer's Disease Fluid Biomarker Research in the Era of COVID-19. Journal of Alzheimer's Disease, 2020, 76, 27-31.	2.6	8
44	Endothelialâ€derived plasma exosome proteins in Alzheimer's disease angiopathy. FASEB Journal, 2020, 34, 5967-5974.	0.5	21
45	Prevalence and Clinical Phenotype of Quadruple Misfolded Proteins in Older Adults. JAMA Neurology, 2020, 77, 1299.	9.0	109
46	One-Year Evaluation of a Targeted Medication Therapy Management Intervention for Older Adults. Journal of Managed Care & Specialty Pharmacy, 2020, 26, 520-528.	0.9	9
47	Brain structure changes over time in normal and mildly impaired aged persons. AIMS Neuroscience, 2020, 7, 120-135.	2.3	5
48	The Effectiveness of Community-based Outreach Events for the Promotion of African American Research Participation. Alzheimer Disease and Associated Disorders, 2020, 34, 344-349.	1.3	0
49	Post-acquisition processing confounds in brain volumetric quantification of white matter hyperintensities. Journal of Neuroscience Methods, 2019, 327, 108391.	2.5	7
50	Reply: LATE to the PART-y. Brain, 2019, 142, e48-e48.	7.6	11
51	White Matter Hyperintensity Regression: Comparison of Brain Atrophy and Cognitive Profiles with Progression and Stable Groups. Brain Sciences, 2019, 9, 170.	2.3	20
52	TDP-43 proteinopathy in aging: Associations with risk-associated gene variants and with brain parenchymal thyroid hormone levels. Neurobiology of Disease, 2019, 125, 67-76.	4.4	25
53	Genetic Sample Provision Among National Alzheimer's Coordinating Center Participants. Journal of Alzheimer's Disease, 2019, 69, 123-133.	2.6	7
54	Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain, 2019, 142, 1503-1527.	7.6	873

#	Article	IF	CITATIONS
55	Tobacco Smoking and Dementia in a Kentucky Cohort: A Competing Risk Analysis. Journal of Alzheimer's Disease, 2019, 68, 625-633.	2.6	11
56	INtervention for Cognitive Reserve Enhancement in delaying the onset of Alzheimer's Symptomatic Expression (INCREASE), a randomized controlled trial: rationale, study design, and protocol. Trials, 2019, 20, 806.	1.6	15
57	Neuropathological Findings of Dementia Associated With Subjective Hearing Loss. Otology and Neurotology, 2019, 40, e883-e893.	1.3	10
58	Perspectives of African American Older Adults on Brain Health. Alzheimer Disease and Associated Disorders, 2019, 33, 354-358.	1.3	3
59	Development of <sup>1</sup> H MRS biomarkers for tracking early predementia Alzheimer disease. Neurology, 2019, 92, 209-210.	1.1	7
60	Visual Arts Education improves self-esteem for persons with dementia and reduces caregiver burden: A randomized controlled trial. Dementia, 2019, 18, 3130-3142.	2.0	20
61	Hippocampal Sclerosis, Argyrophilic Grain Disease, and Primary Age-Related Tauopathy. CONTINUUM Lifelong Learning in Neurology, 2019, 25, 208-233.	0.8	10
62	A Randomized Controlled Trial of Anesthesia Guided by Bispectral Index Versus Standard Care: Effects on Cognition. AANA Journal, 2019, 87, 115-123.	0.4	0
63	Spared behavioral repetition effects in Alzheimer's disease linked to an altered neural mechanism at posterior cortex. Journal of Clinical and Experimental Neuropsychology, 2018, 40, 761-776.	1.3	3
64	High complement levels in astrocyteâ€derived exosomes of Alzheimer disease. Annals of Neurology, 2018, 83, 544-552.	5.3	248
65	Global Cerebral Atrophy Detected by Routine Imaging: Relationship with Age, Hippocampal Atrophy, and White Matter Hyperintensities. Journal of Neuroimaging, 2018, 28, 301-306.	2.0	8
66	The Amygdala as a Locus of Pathologic Misfolding in Neurodegenerative Diseases. Journal of Neuropathology and Experimental Neurology, 2018, 77, 2-20.	1.7	77
67	<i>APOE</i> DNA methylation is altered in Lewy body dementia. Alzheimer's and Dementia, 2018, 14, 889-894.	0.8	17
68	Motivators for Alzheimer's disease clinical trial participation. Aging Clinical and Experimental Research, 2018, 30, 209-212.	2.9	12
69	Age-Related Changes in Headache Days across the Cognitive Spectrum. Pain Medicine, 2018, 19, 1478-1484.	1.9	3
70	Declining levels of functionally specialized synaptic proteins in plasma neuronal exosomes with progression of Alzheimer's disease. FASEB Journal, 2018, 32, 888-893.	0.5	155
71	Public Understanding and Opinions regarding Genetic Research on Alzheimer's Disease. Public Health Genomics, 2018, 21, 228-237.	1.0	5
72	Distinct White Matter Changes Associated with Cerebrospinal Fluid Amyloid-β1-42 and Hypertension. Journal of Alzheimer's Disease, 2018, 66, 1095-1104.	2.6	21

#	Article	IF	CITATIONS
73	Diffuse Amyloid-β Plaques, Neurofibrillary Tangles, and the Impact of APOE in Elderly Persons' Brains Lacking Neuritic Amyloid Plaques. Journal of Alzheimer's Disease, 2018, 64, 1307-1324.	2.6	34
74	Analysis of shared heritability in common disorders of the brain. Science, 2018, 360, .	12.6	1,085
75	Electrophysiological repetition effects in persons with mild cognitive impairment depend upon working memory demand. Neuropsychologia, 2018, 117, 13-25.	1.6	2
76	Alzheimer Disease Clinical Trial Recruitment. Alzheimer Disease and Associated Disorders, 2018, 32, 333-338.	1.3	4
77	Version 3 of the National Alzheimer's Coordinating Center's Uniform Data Set. Alzheimer Disease and Associated Disorders, 2018, 32, 351-358.	1.3	241
78	Risk factors and global cognitive status related to brain arteriolosclerosis in elderly individuals. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 201-216.	4.3	69
79	The Effectiveness of Small-group Community-based Information Sessions on Clinical Trial Recruitment for Secondary Prevention of Alzheimer's Disease. Alzheimer Disease and Associated Disorders, 2017, 31, 141-145.	1.3	11
80	White Matter Hyperintensity Associations with Cerebral Blood Flow in Elderly Subjects Stratified by Cerebrovascular Risk. Journal of Stroke and Cerebrovascular Diseases, 2017, 26, 779-786.	1.6	46
81	Development, validation and application of a new fornix template for studies of aging and preclinical Alzheimer's disease. NeuroImage: Clinical, 2017, 13, 106-115.	2.7	48
82	Outcomes after diagnosis of mild cognitive impairment in a large autopsy series. Annals of Neurology, 2017, 81, 549-559.	5.3	83
83	Altered cargo proteins of human plasma endothelial cell–derived exosomes in atherosclerotic cerebrovascular disease. FASEB Journal, 2017, 31, 3689-3694.	0.5	71
84	Hippocampal Sclerosis in Older Patients: Practical Examples and Guidance With a Focus on Cerebral Age-Related TDP-43 With Sclerosis. Archives of Pathology and Laboratory Medicine, 2017, 141, 1113-1126.	2.5	26
85	A Comparison of Sex Differences in Psychotropic Medication Use in Older People with Alzheimer's Disease in the US and Finland. Drugs and Aging, 2017, 34, 55-65.	2.7	14
86	Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis. Lancet Neurology, The, 2017, 16, 55-65.	10.2	394
87	A Customized Quantitative PCR MicroRNA Panel Provides a Technically Robust Context for Studying Neurodegenerative Disease Biomarkers and Indicates a High Correlation Between Cerebrospinal Fluid and Choroid Plexus MicroRNA Expression. Molecular Neurobiology, 2017, 54, 8191-8202.	4.0	16
88	Linking tuberous sclerosis complex, excessive mTOR signaling, and age-related neurodegeneration: a new association between TSC1 mutation and frontotemporal dementia. Acta Neuropathologica, 2017, 134, 813-816.	7.7	11
89	Dementia for the Primary Care Provider. Primary Care - Clinics in Office Practice, 2017, 44, 439-456.	1.6	7
90	Challenges and Considerations Related to Studying Dementia in Blacks/African Americans. Journal of Alzheimer's Disease, 2017, 60, 1-10.	2.6	48

#	Article	IF	CITATIONS
91	[P4–144]: CLINICAL IMAGING, COGNITIVE, AND GENETIC RISK PROFILES IN INCIDENT MCI FOR THE PREDICTION OF LONGâ€TERM NEUROPATHOLOGICAL OUTCOMES AT AUTOPSY. Alzheimer's and Dementia, 2017, 13, P1313	N <sub>0.8</sub>	0
92	[O1–10–02]: CEREBROVASCULAR DISEASE AND ALZHEIMER'S DISEASE, BUT NOT AGING, ARE ASSOCIATED WITH MODERATE TO SEVERE GLOBAL CEREBRAL ATROPHY SEEN ON CLINICAL BRAIN IMAGING STUDIES. Alzheimer's and Dementia, 2017, 13, P214.	0.8	0
93	Low Arousal Positive Emotional Stimuli Attenuate Aberrant Working Memory Processing in Persons with Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2017, 60, 1333-1349.	2.6	1
94	Functional human GRIN2B promoter polymorphism and variation of mental processing speed in older adults. Aging, 2017, 9, 1293-1306.	3.1	5
95	Alzheimer's Biomarkers are Correlated with Brain Connectivity in Older Adults Differentially during Resting and Task States. Frontiers in Aging Neuroscience, 2016, 8, 15.	3.4	28
96	Ruralâ€Urban Differences in Alzheimer's Disease and Related Disorders Diagnostic Prevalence in Kentucky and West Virginia. Journal of Rural Health, 2016, 32, 314-320.	2.9	43
97	"New Old Pathologiesâ€: AD, PART, and Cerebral Age-Related TDP-43 With Sclerosis (CARTS). Journal of Neuropathology and Experimental Neurology, 2016, 75, 482-498.	1.7	130
98	Decreased synaptic proteins in neuronal exosomes of frontotemporal dementia and Alzheimer's disease. FASEB Journal, 2016, 30, 4141-4148.	0.5	281
99	Plasma neuronal exosomal levels of Alzheimer's disease biomarkers in normal aging. Annals of Clinical and Translational Neurology, 2016, 3, 399-403.	3.7	56
100	Peripheral (deep) but not periventricular <scp>MRI</scp> white matter hyperintensities are increased in clinical vascular dementia compared to Alzheimer's disease. Brain and Behavior, 2016, 6, e00438.	2.2	41
101	Extracellular vesicle-associated Aβ mediates trans-neuronal bioenergetic and Ca2+-handling deficits in Alzheimer's disease models. Npj Aging and Mechanisms of Disease, 2016, 2, .	4.5	102
102	Selfâ€Reported Sleep Apnea and Dementia Risk: Findings from the Prevention of Alzheimer's Disease with Vitamin E and Selenium Trial. Journal of the American Geriatrics Society, 2016, 64, 2472-2478.	2.6	23
103	Genomics and CSF analyses implicate thyroid hormone in hippocampal sclerosis of aging. Acta Neuropathologica, 2016, 132, 841-858.	7.7	28
104	Aging-related tau astrogliopathy (ARTAG): harmonized evaluation strategy. Acta Neuropathologica, 2016, 131, 87-102.	7.7	380
105	Brain pathologies in extreme old age. Neurobiology of Aging, 2016, 37, 1-11.	3.1	94
106	Hippocampal Sclerosis but Not Normal Aging or Alzheimer Disease Is Associated With TDP-43 Pathology in the Basal Forebrain of Aged Persons. Journal of Neuropathology and Experimental Neurology, 2016, 75, 397-407.	1.7	40
107	A novel Alzheimer disease locus located near the gene encoding tau protein. Molecular Psychiatry, 2016, 21, 108-117.	7.9	260
108	A clinical trial to validate eventâ€related potential markers ofÂAlzheimer'sÂdisease in outpatient settings. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 387-394.	2.4	38

#	Article	IF	CITATIONS
109	P3-288: A randomized, double-blind, placebo-controlled, multiple ascending dose study of hdac inhibition for modulation of apoj/clusterin expression as a risk factor for Alzheimer's disease. , 2015, 11, P742-P743.		0
110	Innovation in Stroke Care Quality. Quality Management in Health Care, 2015, 24, 135-139.	0.8	2
111	Discrimination of Mild Cognitive Impairment and Alzheimer's Disease Using Transfer Entropy Measures of Scalp EEG. Journal of Healthcare Engineering, 2015, 6, 55-70.	1.9	32
112	Rarity of the Alzheimer Disease–Protective <i>APP</i> A673T Variant in the United States. JAMA Neurology, 2015, 72, 209.	9.0	41
113	P1-299: A phase i, randomized, double-blind, placebo-controlled, multiple ascending dose study of AT-001 yeast selenium for the prevention of Alzheimer's disease. , 2015, 11, P471-P471.		1
114	Hippocampal Sclerosis of Aging Can Be Segmental. Journal of Neuropathology and Experimental Neurology, 2015, 74, 642-652.	1.7	31
115	Sugihara causality analysis of scalp EEG for detection of early Alzheimer's disease. NeuroImage: Clinical, 2015, 7, 258-265.	2.7	58
116	PART, a distinct tauopathy, different from classical sporadic Alzheimer disease. Acta Neuropathologica, 2015, 129, 757-762.	7.7	139
117	Cerebrospinal Fluid Vascular Endothelial Growth Factor. JAMA Neurology, 2015, 72, 502.	9.0	Ο
118	Assessing the Discriminant Ability, Reliability, and Comparability of Multiple Short Forms of the Boston Naming Test in an Alzheimer's Disease Center Cohort. Dementia and Geriatric Cognitive Disorders, 2015, 39, 215-227.	1.5	26
119	ABCC9/SUR2 in the brain: Implications for hippocampal sclerosis of aging and a potential therapeutic target. Ageing Research Reviews, 2015, 24, 111-125.	10.9	60
120	Musical Training and Late-Life Cognition. American Journal of Alzheimer's Disease and Other Dementias, 2014, 29, 333-343.	1.9	44
121	Effects of Multiple Genetic Loci on Age at Onset in Late-Onset Alzheimer Disease. JAMA Neurology, 2014, 71, 1394.	9.0	166
122	Self-Reported Head Injury and Risk of Late-Life Impairment and AD Pathology in an AD Center Cohort. Dementia and Geriatric Cognitive Disorders, 2014, 37, 294-306.	1.5	65
123	Dysregulation of leptin signaling in Alzheimer disease: evidence for neuronal leptin resistance. Journal of Neurochemistry, 2014, 128, 162-172.	3.9	110
124	Spectral and complexity analysis of scalp EEG characteristics for mild cognitive impairment and early Alzheimer's disease. Computer Methods and Programs in Biomedicine, 2014, 114, 153-163.	4.7	120
125	Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurology, The, 2014, 13, 614-629.	10.2	2,657
126	Arteriolosclerosis that affects multiple brain regions is linked to hippocampal sclerosis of ageing. Brain, 2014, 137, 255-267.	7.6	103

#	Article	IF	CITATIONS
127	Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathologica, 2014, 128, 755-766.	7.7	1,060
128	Self-reported memory complaints. Neurology, 2014, 83, 1359-1365.	1.1	151
129	ABCC9 gene polymorphism is associated with hippocampal sclerosis of aging pathology. Acta Neuropathologica, 2014, 127, 825-843.	7.7	70
130	Frontal white matter integrity in adults with Down syndrome with and without dementia. Neurobiology of Aging, 2014, 35, 1562-1569.	3.1	72
131	Diagnostic accuracy and practice effects in the National Alzheimer's Coordinating Center Uniform Data Set neuropsychological battery. Alzheimer's and Dementia, 2014, 10, 675-683.	0.8	31
132	Nutrition and prevention of Alzheimerââ,¬â"¢s dementia. Frontiers in Aging Neuroscience, 2014, 6, 282.	3.4	72
133	Hippocampal sclerosis of aging, a prevalent and high-morbidity brain disease. Acta Neuropathologica, 2013, 126, 161-177.	7.7	156
134	APOE Ϊμ4 Increases Risk for Dementia in Pure Synucleinopathies. JAMA Neurology, 2013, 70, 223.	9.0	302
135	Resting EEG Discrimination of Early Stage Alzheimer's Disease from Normal Aging Using Inter-Channel Coherence Network Graphs. Annals of Biomedical Engineering, 2013, 41, 1233-1242.	2.5	41
136	APOE-Îμ2 and APOE-Îμ4 Correlate With Increased Amyloid Accumulation in Cerebral Vasculature. Journal of Neuropathology and Experimental Neurology, 2013, 72, 708-715.	1.7	94
137	Repeated retrieval during working memory is sensitive to amnestic mild cognitive impairment. Journal of Clinical and Experimental Neuropsychology, 2013, 35, 946-959.	1.3	9
138	Adjusting for Mortality when Identifying Risk Factors for Transitions to Mild Cognitive Impairment and Dementia. Journal of Alzheimer's Disease, 2013, 35, 823-832.	2.6	28
139	University of Kentucky Sanders-Brown Healthy Brain Aging Volunteers: Donor Characteristics, Procedures and Neuropathology. Current Alzheimer Research, 2012, 9, 724-733.	1.4	146
140	Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature. Journal of Neuropathology and Experimental Neurology, 2012, 71, 362-381.	1.7	1,599
141	Substantia nigra depigmentation and exposure to encephalitis lethargica. Annals of Neurology, 2012, 72, 912-917.	5.3	7
142	Preclinical AD Workgroup staging: pathological correlates and potential challenges. Neurobiology of Aging, 2012, 33, 622.e1-622.e16.	3.1	62
143	Antioxidants for Alzheimer Disease. Archives of Neurology, 2012, 69, 836-41.	4.5	314
144	Attention-Deficit/Hyperactivity Disorder in Older Adults: Prevalence and Possible Connections to Mild Cognitive Impairment. Current Psychiatry Reports, 2012, 14, 552-560.	4.5	49

#	Article	IF	CITATIONS
145	"End-Stage―Neurofibrillary Tangle Pathology in Preclinical Alzheimer's Disease: Fact or Fiction?. Journal of Alzheimer's Disease, 2011, 25, 445-453.	2.6	42
146	Prediction of Preclinical Alzheimer's Disease: Longitudinal Rates of Change in Cognition. Journal of Alzheimer's Disease, 2011, 25, 707-717.	2.6	39
147	Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nature Genetics, 2011, 43, 436-441.	21.4	1,676
148	Management of frontotemporal dementia: targeting symptom management in such a heterogeneous disease requires a wide range of therapeutic options. Neurodegenerative Disease Management, 2011, 1, 141-156.	2.2	22
149	Alzheimer's disease is not "brain aging― neuropathological, genetic, and epidemiological human studies. Acta Neuropathologica, 2011, 121, 571-587.	7.7	273
150	Medical Management of Frontotemporal Dementias: The Importance of the Caregiver in Symptom Assessment and Guidance of Treatment Strategies. Journal of Molecular Neuroscience, 2011, 45, 713-723.	2.3	17
151	Hippocampal sclerosis in advanced age: clinical and pathological features. Brain, 2011, 134, 1506-1518.	7.6	220
152	Conceptual Evolution in Alzheimer's Disease: Implications for Understanding the Clinical Phenotype of Progressive Neurodegenerative Disease. Journal of Alzheimer's Disease, 2010, 19, 253-272.	2.6	74
153	Low sensitivity in clinical diagnoses of dementia with Lewy bodies. Journal of Neurology, 2010, 257, 359-366.	3.6	233
154	Association between male gender and cortical Lewy body pathology in large autopsy series. Journal of Neurology, 2010, 257, 1875-1881.	3.6	107
155	Modeling the Association between 43 Different Clinical and Pathological Variables and the Severity of Cognitive Impairment in a Large Autopsy Cohort of Elderly Persons. Brain Pathology, 2010, 20, 66-79.	4.1	204
156	Omega-3 fatty acids: potential role in the management of early Alzheimer's disease. Clinical Interventions in Aging, 2010, 5, 45.	2.9	143
157	Comparison of Recruitment Efforts Targeted at Primary Care Physicians Versus the Community at Large for Participation in Alzheimer Disease Clinical Trials. Alzheimer Disease and Associated Disorders, 2010, 24, 165-170.	1.3	30
158	Prodromal clinical manifestations of neuropathologically confirmed Lewy body disease. Neurobiology of Aging, 2010, 31, 1805-1813.	3.1	93
159	Acetylcholinesterase Inhibitor Treatment is Associated with Relatively Slow Cognitive Decline in Patients with Alzheimer's Disease and AD + DLB. Journal of Alzheimer's Disease, 2009, 16, 29-34.	2.6	25
160	Primary Diffuse Leptomeningeal Gliomatosis. European Neurology, 2009, 62, 16-22.	1.4	18
161	Brains With Medial Temporal Lobe Neurofibrillary Tangles But No Neuritic Amyloid Plaques Are a Diagnostic Dilemma But May Have Pathogenetic Aspects Distinct From Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2009, 68, 774-784.	1.7	92
162	Lewy Body Pathology in Normal Elderly Subjects. Journal of Neuropathology and Experimental Neurology, 2009, 68, 816-822.	1.7	178

#	Article	IF	CITATIONS
163	Is passive immunization for Alzheimer's disease â€~alive and well' or â€~dead and buried'?. Expert Opinion Biological Therapy, 2009, 9, 481-491.	on 3.1	28
164	Alzheimer's-type neuropathology in the precuneus is not increased relative to other areas of neocortex across a range of cognitive impairment. Neuroscience Letters, 2009, 450, 336-339.	2.1	66
165	Age and apoE associations with complex pathologic features in Alzheimer's disease. Journal of the Neurological Sciences, 2008, 273, 34-39.	0.6	30
166	Clinical Features of Mild Cognitive Impairment Differ in the Research and Tertiary Clinic Settings. Dementia and Geriatric Cognitive Disorders, 2008, 26, 187-192.	1.5	31
167	Clinicopathologic Correlations in a Large Alzheimer Disease Center Autopsy Cohort. Journal of Neuropathology and Experimental Neurology, 2007, 66, 1136-1146.	1.7	258
168	Chapter 3 Mild Cognitive Impairment. Blue Books of Neurology, 2007, , 59-87.	0.1	2
169	Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria. Lancet Neurology, The, 2007, 6, 734-746.	10.2	3,755
170	EEG Changes in a Patient With Steroid-Responsive Encephalopathy Associated With Antibodies to Thyroperoxidase (SREAT, Hashimoto's Encephalopathy). Journal of Clinical Neurophysiology, 2006, 23, 371-373.	1.7	45
171	Argyrophilic Grain Disease in Demented Subjects Presenting Initially With Amnestic Mild Cognitive Impairment. Journal of Neuropathology and Experimental Neurology, 2006, 65, 602-609.	1.7	48
172	Neuropathologic Outcome of Mild Cognitive Impairment Following Progression to Clinical Dementia. Archives of Neurology, 2006, 63, 674.	4.5	377
173	Depression, Apolipoprotein E Genotype, and the Incidence of Mild Cognitive Impairment. Archives of Neurology, 2006, 63, 435.	4.5	206
174	Neuropathologic Features of Amnestic Mild Cognitive Impairment. Archives of Neurology, 2006, 63, 665.	4.5	562
175	Pseudotumor cerebri reversed by cardiac septal defect repair. Neurology, 2003, 60, 2016-2017.	1.1	8
176	cAMP-Dependent Protein Kinase Phosphorylations on Tau in Alzheimer's Disease. Journal of Neuroscience, 1999, 19, 7486-7494.	3.6	185
177	Hierarchical Phosphorylation of Recombinant Tau by the Paired-Helical Filament-Associated Protein Kinase Is Dependent on Cyclic AMP-Dependent Protein Kinase. Journal of Neurochemistry, 1999, 72, 214-224.	3.9	64
178	Sequence requirements for formation of conformational variants of tau similar to those found in Alzheimer's disease. Journal of Neuroscience Research, 1999, 55, 713-723.	2.9	110
179	Altered conformation of recombinant frontotemporal dementia-17 mutant tau proteins. Neuroscience Letters, 1999, 260, 153-156.	2.1	42
180	Aberrant Expression of Mitotic Cdc2/Cyclin B1 Kinase in Degenerating Neurons of Alzheimer's Disease Brain. Journal of Neuroscience, 1997, 17, 3588-3598.	3.6	441

#	Article	IF	CITATIONS
181	Alz-50 and MC-1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau. Journal of Neuroscience Research, 1997, 48, 128-132.	2.9	462
182	A Conformation―and Phosphorylationâ€Dependent Antibody Recognizing the Paired Helical Filaments of Alzheimer's Disease. Journal of Neurochemistry, 1997, 69, 2087-2095.	3.9	230